cyproheptadine has been researched along with Parkinson Disease in 4 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fodor, M | 1 |
| Solymosi, L | 1 |
| Szántó, J | 1 |
| Casacchia, M | 1 |
| Carolei, A | 1 |
| Zamponi, A | 1 |
| Agnoli, A | 1 |
| Fazio, C | 1 |
| Papavasilliou, PS | 1 |
| Cotzias, GC | 1 |
| McDowell, FH | 1 |
| Rosal, VL | 1 |
| Sheehan, PJ | 1 |
| Hirschorn, KA | 1 |
| Greenberg, HS | 1 |
2 trials available for cyproheptadine and Parkinson Disease
| Article | Year |
|---|---|
[Evaluation of combined L-dopa-cyproheptadine therapy of patients with Parkinson's disease].
Topics: Clinical Trials as Topic; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Humans; Le | 1980 |
Cyproheptadine in levodopa-induced dyskinesia in parkinsonism.
Topics: Aged; Carbidopa; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-In | 1978 |
2 other studies available for cyproheptadine and Parkinson Disease
| Article | Year |
|---|---|
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; | 1976 |
Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. A case report.
Topics: Aged; Cyproheptadine; Humans; Levodopa; Male; Methysergide; Myoclonus; Neuroleptic Malignant Syndrom | 1988 |